While it only accounts for 8% of its overall revenue, its sales doubled through the first three quarters of 2021.įor the entire fiscal 2021, Globus expects sales of $950 million and non-GAAP EPS of $2.00. One highlight: The company's Enabling Technologies division, which operates the ExcelsiusGPS robotic navigation system for more accurate spine surgery. 30, revenues were up 27% to $708 million, while profits popped 82.4% to $1.55 per share.
Since its founding, Globus has introduced more than 220 products into 51 countries worldwide.ĭespite COVID-19 putting a dent in surgical procedures, the company's Q3 2021 sales increased by 6.3% to $229.7 million, while adjusted earnings per share (EPS) of 50 cents were a penny higher than the year-ago period. Globus Medical ( GMED, $67.58), founded in 2003, focuses on products that treat musculoskeletal conditions. Median target price: $85.92 (27% implied upside).Analysts' opinion: 5 Strong Buy, 4 Buy, 4 Hold, 0 Sell, 0 Strong Sell.Read on as we evaluate 15 of the best mid-cap stocks to buy for 2022 and beyond. Using a baseball analogy, they might not hit you a bunch of home runs, but they're sure to knock in a lot of runners, ultimately producing when it counts. Mid-cap stocks – which Mackenzie refers to as the "sweet spot" of investing – can best be described as consistent performers. So, even though large deals get all the press, it's the smaller acquisitions that happen more often. It found that 91% of the deals were for companies valued between $500 million and $5 billion. Through October 2018, it looked at 11,270 M&A deals over 10 years. So even though large deals get a lot of press, small- and mid-cap takeovers happen far more often. Mackenzie pointed to 10 years of data through October 2018 showing that, of 11,270 mergers and acquisitions, 91% involved sums between $500 million and $5 billion. Enjoy far less analyst coverage than large caps, which offers active managers an edge.
Have historically provided better risk/return characteristics.Give you the stability of large-cap stocks combined with the growth of small-cap stocks.Many of 2022's best mid-cap stocks might just be among 2022's best stocks period.Ī couple years ago, Canadian mutual fund and exchange-traded fund (ETF) provider Mackenzie Financial made a convincing universal case for U.S. Large-cap stocks are valued for their stability and dividends, while small-cap stocks are favored for their growth prospects.īut avoid the happy medium at your own peril. Mid-cap stocks – typically, companies between $2 billion to $10 billion, though some indexes view them differently – are too often overlooked.
0 kommentar(er)
